Benefits
Butyrate production in the gut
C. butyricum MIYAIRI 588 directly produces butyrate — a short-chain fatty acid essential for colonocyte energy, gut barrier function, and anti-inflammatory effects. Mechanism distinguishes it from probiotics that rely on indirect metabolic effects.
Antibiotic-associated diarrhea prevention
Clinical trials show CBM588 reduces incidence of antibiotic-associated diarrhea when taken alongside antibiotic therapy. Heat-stable spore form survives stomach acid and resists destruction by concurrent antibiotic doses.
Irritable bowel syndrome support
Trials in IBS patients show improvements in symptom scores and stool consistency over weeks of supplementation. Mechanism likely involves butyrate-mediated reduction in gut inflammation and barrier strengthening.
Cancer immunotherapy adjunct (emerging)
Emerging trials in cancer patients on immune checkpoint inhibitors (anti-PD-1 antibodies) suggest CBM588 may improve treatment response, possibly through microbiome-immune axis effects. Promising early evidence; oncology supervision required.
Inflammatory bowel disease support
Trials in inflammatory bowel disease show CBM588 may support symptom management as an adjunct to standard therapy. Less robust than the IBS evidence but mechanistically consistent.
Gut barrier function support
Butyrate from CBM588 strengthens tight junctions between colonocytes and reduces intestinal permeability. The mechanism supports its broader anti-inflammatory and immune-modulating benefits across conditions.
Decades-long Japanese safety record
Marketed in Japan since the 1960s with extensive real-world use and safety documentation. The Japanese regulatory framework provides confidence in its tolerability profile across age groups.
Mechanism of action
Butyrate production (distinguishing from Lactobacillus/Bifidobacterium)
C. butyricum is a butyrate producer — distinct from the lactic-acid-producing Lactobacillus and Bifidobacterium probiotics. Butyrate is the primary energy source for colonocytes (60-70% of their energy), supports HDAC inhibition with anti-inflammatory effects, and is the underlying biology supporting many of the observed benefits.
Spore formation with heat and acid resistance
Like other Clostridium species, C. butyricum forms endospores resistant to gastric acid, bile, and heat — enabling reliable transit through the upper GI tract to the colon where it germinates and exerts effects.
C. difficile direct inhibition (Sci Rep 2021 + PMID 21700738)
Multi-modal C. difficile suppression: succinate modulation (preventing the metabolic substrate C. difficile uses for proliferation), fidaxomicin enhancement (synergy with the standard CDI antibiotic), and direct toxicity reduction in vitro.
Mucin layer protection and production
Seki 2003 mechanism — CBM 588 protects and supports production of the mucin layer that physically separates gut bacteria from the epithelium. An intact mucin layer reduces bacterial translocation and supports barrier function.
TNF-α downregulation and IgA upregulation
Sci Rep 2021 — downregulated TNF-α in macrophages of the colon lamina propria while upregulating IgA production via IL-17A CD4+ T cells and plasma B cells. Anti-inflammatory plus enhanced mucosal antibody response — the kind of immune-balance modulation that supports infection resistance without driving inflammation.
Cross-feeding support of beneficial commensals
CBM 588 metabolites (butyrate and others) support growth of native Bifidobacterium, Lactobacillus, and Lactococcus species — indirect microbiome modulation beyond the strain's own activity.
Anti-tumorigenic mechanisms (preclinical for CRC indication)
Butyrate-mediated HDAC inhibition, Treg differentiation, oncogenic MYC destabilization, and thymidylate synthase downregulation — the proposed basis for the colorectal adenomatous polyp recurrence trial (NCT06855355). Currently preclinical mechanism rationale; human cancer-prevention efficacy is pending the trial.
Clinical trials
Nature Scientific Reports 2021, doi:10.1038/s41598-021-94572-z. CBM 588 enhanced C. difficile colonization resistance via metabolic and immune modulation — enhanced fidaxomicin antibacterial activity, negatively modulated gut succinate (substrate for C. difficile), downregulated colon-resident macrophage TNF-α, upregulated IgA through IL-17A CD4+ T cells and plasma B cells, and Th17-enhanced gut epithelial barrier function. The most rigorous mechanism evidence to date supporting the CDI prophylaxis indication.
Liaquat University Pakistan, completed. Butirrisan® 3 tablets/day for 8 weeks vs standard of care (trimebutine + lactose-free, low-residue diet) in IBS-D. Outcome data publication awaited. First registered Caucasian-population trial extending Japanese clinical experience.
Osel Inc Phase 2 RCT in CDI recurrence using MIYA-BM at 2 g BID for 42 days. Withdrawn due to lack of enrollment — not efficacy or safety concerns. Reflects translational challenge between Japanese established clinical use and US RCT recruitment requirements rather than negative findings.
Kaohsiung Medical University randomized crossover trial, currently enrolling by invitation. Anti-tumorigenic mechanism rationale: HDAC inhibition, Treg differentiation, MYC destabilization, thymidylate synthase downregulation. Cancer-prevention application is at the emerging trial stage; outcome data pending.
Seki H et al. 2003. Pediatric antibiotic-associated diarrhea prevention via mucin layer protection and production. Foundational Japanese evidence supporting the 50+ year pediatric use.